Tandem Diabetes sees FY22 revenue at ‘approximately’ $805M, consensus $802.5M

The company previously guided $800M-$805M. CEO John Sheridan says: "A record number of Tandem customers renewed in the fourth quarter, which coupled with strong retention rates, is evidence of the high level of satisfaction people experience with our t:slim X2 with Control-IQ technology. We remain focused on driving growth by bringing the benefits of our current and future technology to more people living with diabetes, and through our scaling renewal opportunities, as we work to deliver outstanding service to our 420,000 customers worldwide."